These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 15748287)

  • 41. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of cost-effectiveness analysis to multiple products: a practical guide.
    Bala MV; Zarkin GA
    Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the value for money of medicines? A registry study.
    Simoens S
    J Clin Pharm Ther; 2012 Apr; 37(2):182-6. PubMed ID: 21812796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing differences in utility scores: a comparison of four widely used preference-based instruments.
    Wee HL; Machin D; Loke WC; Li SC; Cheung YB; Luo N; Feeny D; Fong KY; Thumboo J
    Value Health; 2007; 10(4):256-65. PubMed ID: 17645680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Valuing health for clinical and economic decisions: directions relevant for rheumatologists.
    Harrison MJ; Bansback NJ; Marra CA; Drummond M; Tugwell PS; Boonen A
    J Rheumatol; 2011 Aug; 38(8):1770-5. PubMed ID: 21807800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.
    Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
    Med Care; 2011 Mar; 49(3):267-72. PubMed ID: 21224742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer.
    Grimison PS; Simes RJ; Hudson HM; Stockler MR
    Value Health; 2009 Sep; 12(6):967-76. PubMed ID: 19490566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we derive an 'exchange rate' between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) technique.
    Mortimer D; Segal L; Sturm J
    Health Qual Life Outcomes; 2009 Apr; 7():33. PubMed ID: 19371444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of bootstrap methods for analysing Health-Related Quality of Life outcomes (particularly the SF-36).
    Walters SJ; Campbell MJ
    Health Qual Life Outcomes; 2004 Dec; 2():70. PubMed ID: 15588308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries.
    Flood EM; De Cock E; Mörk AC; Revicki DA
    Health Qual Life Outcomes; 2006 Aug; 4():51. PubMed ID: 16911790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mapping the SF-12 to the HUI3 and VAS in a managed care population.
    Sengupta N; Nichol MB; Wu J; Globe D
    Med Care; 2004 Sep; 42(9):927-37. PubMed ID: 15319619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bias in published cost effectiveness studies: systematic review.
    Bell CM; Urbach DR; Ray JG; Bayoumi A; Rosen AB; Greenberg D; Neumann PJ
    BMJ; 2006 Mar; 332(7543):699-703. PubMed ID: 16495332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-utility analysis of rimonabant in the treatment of obesity.
    Hampp C; Hartzema AG; Kauf TL
    Value Health; 2008; 11(3):389-99. PubMed ID: 18179661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A preference-based index for the SF-12.
    Stratmann-Schoene D; Kuehn T; Kreienberg R; Leidl R
    Health Econ; 2006 Jun; 15(6):553-64. PubMed ID: 16389653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surveillance for isocyanate asthma: a model based cost effectiveness analysis.
    Wild DM; Redlich CA; Paltiel AD
    Occup Environ Med; 2005 Nov; 62(11):743-9. PubMed ID: 16234399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lowering the 'floor' of the SF-6D scoring algorithm using a lottery equivalent method.
    Abellán Perpiñán JM; Sánchez Martínez FI; Martínez Pérez JE; Méndez I
    Health Econ; 2012 Nov; 21(11):1271-85. PubMed ID: 21976290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A synthesis of cost-utility analysis literature in infectious disease.
    Stone PW; Schackman BR; Neukermans CP; Olchanski N; Greenberg D; Rosen AB; Neumann PJ
    Lancet Infect Dis; 2005 Jun; 5(6):383-91. PubMed ID: 15919624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain.
    Hollingworth W; Deyo RA; Sullivan SD; Emerson SS; Gray DT; Jarvik JG
    Health Econ; 2002 Jan; 11(1):71-85. PubMed ID: 11788983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States.
    Yaghoubi M; Adibi A; Zafari Z; FitzGerald JM; Aaron SD; Johnson KM; Sadatsafavi M
    J Allergy Clin Immunol; 2020 May; 145(5):1367-1377.e4. PubMed ID: 31837372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysing risk attitudes to time.
    Oliver A; Cookson R
    Health Econ; 2010 Jun; 19(6):644-55. PubMed ID: 19424992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.